Share
12,497 Posts.
lightbulb Created with Sketch. 379
clock Created with Sketch. 03/01/18
13:10
Share
Originally posted by RBx
↑
With protracted litigation over the ownership of NOX66 no longer a threat, it is timely to look at the patent position for NOX66.the objective of the manufacture process is not to admix, or to mingle, or to blend the suppository base with the isoflavonoid as generally occurs in pharmacy practice of admixing components, as it is believed that the resulting admixture would have a lower likelihood of providing therapeutic benefit ".In a preferred embodiment, all of the isoflavonoid added to a dosage unit is DISSOLVED in the base (my emphasis). In this embodiment, no isoflavonoid is left to admixture with the suppository base. This is believed to increase the likelihood of the uptake of all the isoflavonoid given in the dosage unit ".none of the prior art documents disclose dissolving the isoflavonoid compounds in the oleaginous base " but rejects all other claims because the scope of these claims include compounds "contained" in the base (rather than being "dissolved" in the base). This seems to be splitting hairs, because the text clearly stated that isoflavonoids must be dissolved in the base but in the claims this is at times described as "contained or dissolved in the base".
Expand
I think I understand what you are saying Rbx?
(20min delay)
